Background: Guidelines addressing the management of venous thromboembolism (VTE) in
cancer patients are heterogeneous and their implementation has been suboptimal …

Therapeutic options for the management of venous thromboembolism (VTE) in patients with
cancer remain very limited. Although low-molecular-weight heparin monotherapy has been …

Venous thromboembolism (VTE) is a major health problem among patients with cancer, its
incidence in this particular population is widely increasing. Although VTE is associated with …

Use of inferior vena cava (IVC) filters has increased dramatically in recent decades, despite
a lack of evidence that their use has impacted venous thromboembolism (VTE)‐related …

Venous thromboembolism (VTE) is one of the three most common cardiovascular diseases
in the United States. It is also a leading cause of death among patients with cancer. Cancer …

Venous thromboembolism is common. Most pulmonary emboli arise as thromboses in the
deep veins of the lower extremities and may result in serious complications. Inferior vena …

The close relationship between malignancy and venous thromboembolism (VTE) is well
established, with malignancy increasing VTE risk and accounting for a substantial proportion …

Venous thromboembolism (VTE) is a major therapeutic issue in cancer patients. Advances
in this field and heterogeneities in clinical practices prompted us to establish guidelines in …

Background There are few studies that have determined clinical outcomes following inferior
vena cava filter (IVCF) insertion in cancer patients hospitalized for acute deep-vein …

Abstract Purpose We evaluated the Gunther Tulip (GT) retrievable inferior vena cava (IVC)
filter with regard to indications, filtration efficacy, complications, retrieval window, and use of …